Content specific to this active ingredient… Drug Information Prescribing and patient information from leading authorities Drug Master Files Type 2 master files on file at the FDA Safety Information For prescription drugs containing this active ingredient Exclusivity Patent and market exclusivity data Federal Register FR search results for this API FDA Approved Labelling Information found in this drug's package inserts Research Links Chemical identification and research citations Title 21 Code of Federal Regulations FDA regulations for this API

FDA Approval Activities for this Drug… ETHYOL (amifostine) Injection, MedImmune Oncology, NDA 20-221/S-017 3/27/03 4/15/03 4/1/03 ETHYOL (amifostine) Injection, MedImmune Oncology, NDA 20-221/S-015 2/20/02 2/21/02 ETHYOL (amifostine) Injection, 500mg (amifostine anhydrous base), US Bioscience NDA 20-221/S-012 6/24/99 6/25/99 6/25/99 6/22/01 Ethyol Indication: To reduce the incidence of moderate to severe xerostomia in patients undergoing post-ooperative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands (see Clinical Studies). | Ethyol (amifostine) Injection, MedImmune Oncology, Labeling Revision | Amifostine Injection, Sun Pharma, Tentative Approval | Amifostine Injection, Sun Pharma, Approval | Ethyol (amifostine) Injection, MedImmune, Labeling Revision ^ FDA's latest approval appears at the bottom of this list. ^                                                                       A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z Health Topics | For Industry | DMF Index | Pharma Job Search | Pharma Company News | Best Phone © 2012 Betterchem.com